(2R)-L-gamma-Glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenylglycine 1,3-diethyl ester
(S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-2-ethoxy-2-oxo-1-phenylethyl)amino)-1-oxopropan-2-yl)amino)-5-oxopentanoate
CAS: 168682-53-9
Molecular Formula: C27H35N3O6S
(2R)-L-gamma-Glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenylglycine 1,3-diethyl ester - Names and Identifiers
(2R)-L-gamma-Glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenylglycine 1,3-diethyl ester - Physico-chemical Properties
| Molecular Formula | C27H35N3O6S |
| Molar Mass | 529.65 |
| Density | 1.216±0.06 g/cm3(Predicted) |
| Melting Point | >94°C (dec.) |
| Boling Point | 749.7±60.0 °C(Predicted) |
| Solubility | DMSO : 80 mg/mL mother liquor preservation: sub-package and freeze storage to avoid repeated freezing and thawing;-20 ℃,1 month;-80 ℃,6 months (after dilution, the solution temperature is low and storage may precipitate, try to use it now) Cell experiment: Dissolve with DMSO first: dilute with culture medium then, and the dilution process is recommended to be carried out in stages to avoid too fast concentration change leading to compound precipitation. If the compound is precipitated during the dilution process, it can be redissolved by ultrasound. During dilution, ensure that the final concentration of DMSO in the working fluid should be below 0.1% as far as possible, and the maximum should not exceed 0.5%, and set up a DMSO control group with corresponding concentration. Animal experiment: Dissolve with DMSO first: dilute with water or normal saline, etc. The dilution process is recommended to be carried out in sections to avoid excessive concentration changes leading to compound p |
| Appearance | Solid |
| Color | White to Off-White |
| pKa | 12?+-.0.46(Predicted) |
| Storage Condition | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
| Use | Ezatiostat is a liposomal small-molecule glutathione analog inhibitor of glutathione S-transferase (GST) P1-1 with hematopoiesis-stimulating activity. After intracellular de-esterification, the active form of ezatiostat binds to and inhibits GST P1-1, thereby restoring Jun kinase and MAPK pathway activities and promoting MAPK-mediated cellular proliferation and differentiation pathways. This agent promotes the proliferation and maturation of hematopoietic precursor cells, granulocytes, monocytes, erythrocytes and platelets. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). |
| Target | Glutathione S-transferase P1-1 (GSTP1) |
| In vitro study | Ezatiostat causes dissociation of the enzyme from the jun-N-terminal kinase/c-Jun (JNK/JUN) complex, leading to JNK activation by phosphorylation. The therapeutic action of ezatiostat appears to include both proliferation of normal myeloid progenitors as well as apoptosis of the malignant clone. Selection of a resistant clone of an HL60 tumor cell line through chronic exposure to Ezatiostat (TLK199) results in cells with elevated activities of c-Jun NH2 terminal kinase (JNK1) and ERK1/ERK2, and allowes the cells to proliferate under stress conditions that induced high levels of apoptosis in the wild type cells. |
| In vivo study | Administration of Ezatiostat (TLK199), stimulates both lymphocyte production and bone marrow progenitor (colony-forming unit-granulocyte macrophage) proliferation, but only in glutathione S-transferase P1-1 (GSTP1 +/+ ) and not in GSTP1 -/- animals. |
(2R)-L-gamma-Glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenylglycine 1,3-diethyl ester - Reference
| Reference Show more | 1: Galili N, Tamayo P, Botvinnik OB, Mesirov JP, Brooks MR, Brown G, Raza A. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome. J Hematol Oncol. 2012 May 6;5:20. doi: 10.1186/1756-8722-5-20. PubMed PMID: 22559819; PubMed Central PMCID: PMC3407785. 2: Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). J Hematol Oncol. 2012 Apr 30;5:18. doi: 10.1186/1756-8722-5-18. PubMed PMID: 22546242; PubMed Central PMCID: PMC3416694. 3: Lyons RM, Wilks ST, Young S, Brown GL. Oral ezatiostat HCl (Telintra®, TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor. J Hematol Oncol. 2011 Nov 2;4:43. doi: 10.1186/1756-8722-4-43. PubMed PMID: 22047626; PubMed Central PMCID: PMC3235963. 4: Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer. 2012 Apr 15;118(8):2138-47. doi: 10.1002/cncr.26469. Epub 2011 Sep 1. PubMed PMID: |
(2R)-L-gamma-Glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenylglycine 1,3-diethyl ester - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.888 ml | 9.44 ml | 18.88 ml |
| 5 mM | 0.378 ml | 1.888 ml | 3.776 ml |
| 10 mM | 0.189 ml | 0.944 ml | 1.888 ml |
| 5 mM | 0.038 ml | 0.189 ml | 0.378 ml |
Last Update：2024-01-02 23:10:35
(2R)-L-gamma-Glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenylglycine 1,3-diethyl ester - Introduction
(S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-yl)amino)-1-oxopropan-2-yl)amino)-5-oxopentanoate is a chemical substance, also known as tlk199. It is a small molecule inhibitor that can regulate the oxidation/reduction balance within the cell, thereby affecting cell signaling and growth.
(S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-) amino) the main use of-1-oxopropan-2-yl)amino)-5-oxopentanoate is to treat a blood disorder called myelodysplastic syndrome (MDS). MDS is a group of diseases of abnormal proliferation of hematopoietic cells that can develop into leukemia. (S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-yl)amino)-1-oxopropan-2-yl)amino)-5-oxopentanoate can reduce the proliferation of abnormal cells and promote their differentiation by inhibiting an enzyme activity in bone marrow cells. It is used as a first-line treatment or in patients who cannot tolerate other treatments.
(S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-) amino)-1-oxopropan-2-yl)amino)-5-oxopentanoate is obtained by chemical synthesis. It is synthesized by a series of reaction steps to a specific compound.
As for safety information,(S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-amino) amino)-1-oxopropan-2-yl)amino)-5-oxopentanoate has shown certain safety and tolerability in clinical trials. Some patients may experience mild adverse reactions, including nausea, vomiting, fatigue and other symptoms. But according to the results of the current study, these side effects are usually reversible and relatively mild. However, there may still be potential unknown risks and side effects, so when using (S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-,) amino)-1-oxopropan-2-yl)amino)-5-oxopentanoate is required when closely monitoring the patient's condition and following the doctor's instructions.
(S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-) amino) the main use of-1-oxopropan-2-yl)amino)-5-oxopentanoate is to treat a blood disorder called myelodysplastic syndrome (MDS). MDS is a group of diseases of abnormal proliferation of hematopoietic cells that can develop into leukemia. (S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-yl)amino)-1-oxopropan-2-yl)amino)-5-oxopentanoate can reduce the proliferation of abnormal cells and promote their differentiation by inhibiting an enzyme activity in bone marrow cells. It is used as a first-line treatment or in patients who cannot tolerate other treatments.
(S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-) amino)-1-oxopropan-2-yl)amino)-5-oxopentanoate is obtained by chemical synthesis. It is synthesized by a series of reaction steps to a specific compound.
As for safety information,(S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-amino) amino)-1-oxopropan-2-yl)amino)-5-oxopentanoate has shown certain safety and tolerability in clinical trials. Some patients may experience mild adverse reactions, including nausea, vomiting, fatigue and other symptoms. But according to the results of the current study, these side effects are usually reversible and relatively mild. However, there may still be potential unknown risks and side effects, so when using (S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-,) amino)-1-oxopropan-2-yl)amino)-5-oxopentanoate is required when closely monitoring the patient's condition and following the doctor's instructions.
Last Update：2024-04-09 22:09:11
Supplier List
Product Name: (S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-2-ethoxy-2-oxo-1-phenylethyl)amino)-1-oxopropan-2-yl)amino)-5-oxopentanoate Visit Supplier Webpage Request for quotation
CAS: 168682-53-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 168682-53-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: (S)-ethyl 2-amino-5-(((R)-3-(benzylthio)-1-(((S)-2-ethoxy-2-oxo-1-phenylethyl)amino)-1-oxopropan-2-yl)amino)-5-oxopentanoate Visit Supplier Webpage Request for quotation
CAS: 168682-53-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 168682-53-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History